Overview
Serimmune is an immune intelligence company providing advanced serum antibody profiling through its proprietary SERA (Serum Epitope Repertoire Analysis) platform. The company combines bacterial display peptide library technology, next-generation sequencing, and machine learning to deliver comprehensive immune response mapping for diagnostics, vaccine development, and therapeutic research. Serimmune's capabilities include precision Lyme disease diagnostics, Long COVID immune profiling, and pathogen exposure assessment from minimal serum samples. Now part of Infinity Bio, the company continues expanding its epitope profiling and antibody reactome services for pharmaceutical and research applications.
Frequently asked questions
- What is Serimmune's core technology platform?
- Serimmune's proprietary SERA platform uses a 10 billion random bacterial peptide display library combined with next-generation sequencing and machine learning to profile antibody repertoires and identify antigens and epitopes associated with diseases from minimal serum samples (less than 50 microliters).
- What diagnostic applications does Serimmune offer?
- Serimmune has developed best-in-class antibody tests for Lyme disease diagnostics, Long COVID immune profiling, and pathogen exposure assessment including viral infections like SARS-CoV-2 and Epstein-Barr virus. The platform can distinguish between different infection stages and identify past and current immune responses.
- What are the performance characteristics of Serimmune's assays?
- Serimmune's SERA assay demonstrates 98.6% specificity and improved sensitivity compared to standard assays. For Lyme disease testing, the platform improved sensitivity from 62% to 77% while assessing hundreds of potential epitopes for more precise antibody findings.
- Does Serimmune support remote or at-home testing?
- Yes, Serimmune combines machine learning with at-home testing capabilities to enable remote clinical testing and patient accessibility for immune response profiling.
- What is Serimmune's current corporate status?
- Serimmune is now part of Infinity Bio, Inc., a global leader in antibody reactome services. This partnership combines Serimmune's epitope profiling and discovery platform with Infinity Bio's advanced technologies to expand capabilities in immunology research and translational science.